Creso Pharma (ASX:CPH) primed to profit from potential changes to U.S. psychedelics laws, page-28

Good to see a well researched post from a non-holder. Usually it's just people spewing baseless crap, for spurious reasons. Hard to tell the selfish day traders from the serial pests. Somewhere in between there's the odd non-holder who offers some basis to their contrarian views.

Last year was not a good year for CPH, nor was it for any cannabis stock. December 2020 was the turning point for the industry, and I think this should be used as the baseline (or "starting point") for the industry, given the UN/EU/TGA reclass rulings on cannabis. True, the cap vs revenue ratio leaves much to be desired, but you're looking at it from a short term view.

The market is still opening up, and as it currently stands there's too many players and not enough demand globally. This will shift as regulatory conditions become more favourable across more and more countries.

Bruce Linton has done wonders for CPH at the strategic level. You need only look to the quality of announcements to see this. CPH has a global footprint (which many other ASX listed cannabis stocks do not currently have) and a new, sizeable, enviable addressable global market in psychedelics, which again, no other ASX listed stock owns 100%.

This global footprint and market broadening expansion of course comes at a high cost, and only those willing to invest long term will see benefit (or those who try to roll the dice at day trading). The excessive posts regarding revenue, high management expenditure are repeated daily. These are short term views.

Long term investors such as John Hancock, S3 Consortium, L1 Global MasterOpportunities Fund and other retail long termers hold a different view.

I think these long term views need to be accepted as well.